BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Employees - 65,
CEO - Dr. Jay M. Short Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 19.47M
Altman ZScore(max is 10): -13.68, Piotroski Score(max is 10): 3, Working Capital: $41105000, Total Assets: $62236000, Retained Earnings: $-471155000, EBIT: -86464000, Total Liabilities: $39268000, Revenue: $12706000
- Current Price $0.69 - Analyst Target Price $8.67| Ticker | BCAB |
| Index | - |
| Curent Price | 0.69 |
| Change | -41.82% |
| Market Cap | 19.47M |
| Average Volume | 1.30M |
| Income | -81.82M |
| Sales | 11.00M |
| Book Value/Share | 0.48 |
| Cash/Share | 2.01 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 65 |
| Moving Avg 20days | -53.15% |
| Moving Avg 50days | -60.35% |
| Moving Avg 200days | -65.45% |
| Shares Outstanding | 48.35M |
| Earnings Date | Nov 07 AMC |
| Inst. Ownership | 32.74% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 1.77 |
| Price/Book | 1.46 |
| Price/Cash | 0.34 |
| Price/FCF | - |
| Quick Ratio | 3.11 |
| Current Ratio | 3.11 |
| Debt/Equity | 0.05 |
| Return on Assets | -76.61% |
| Return on Equity | -139.06% |
| Return on Investment | -356.22% |
| Gross Margin | 90.32% |
| Ops Margin | -783.95% |
| Profit Margin | -743.79% |
| RSI | 19.59 |
| BETA(β) | 1.09 |
| From 52week Low | -39.27% |
| From 52week High | -82.78% |
| EPS | -1.70 |
| EPS next Year | -1.41 |
| EPS next Qtr | -0.39 |
| EPS this Year | 40.93% |
| EPS next 5 Year | - |
| EPS past 5 Year | -25.30% |
| Sales past 5 Year | -56.91% |
| EPS Y/Y | 35.84% |
| Sales Y/Y | - |
| EPS Q/Q | 68.57% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 46.77% |
| ATR(14) | 0.17 |
| Perf Week | -52.26% |
| Perf Month | -53.22% |
| Perf Quarter | -58.30% |
| Perf Year | -65.73% |
| Perf YTD | -71.86% |
| Target Price | 8.67 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer